Volume 34, 10 October 2003 10/2003
 
  SPOT ON
 

Do we need drug representatives?

 
  THERAPIES FROM A CRITICAL VIEW POINT
 

Acute coronary syndrome: Early catheter intervention or prolonged antithrombotic pretreatment?
Asthma: Long-acting betamimetics to be used only in combination with corticosteroids

 
  NEW ON THE MARKET
 

TNF- blocker adalimumab (HUMIRA) to treat rheumatoid arthritis

 
  REVIEW
 

Treatment of hyperhidrosis: Botulinum toxin type A etc.

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Pneumococcal vaccination - for whom?
Omeprazole via PEG tube
Old registered drugs and what happens then

 
  QUACKERY
 

Indian herbal tea against cancer?
Signs of quackery

 
  IN BRIEF
 

Influenza vaccines 2003/2004
Antiphospholipid syndrome: High-intensity anticoagulation?
Distribution of CASODEX 150 mg to be stopped
Incomplete publication of large oncology trials

 
  CURRENT ADR NETWORK REPORT

Hazardous drop in blood pressure due to alfuzosin (e.g. URION)

 
© arznei-telegramm 10/2003